Ibrutinib got a pretty clean approval from the FDA today for CLL.
Anyone who had at least one prior therapy is a candidate for the drug.
For most but not all us that is very good news that means it should be much easier to get the drug outside of a clinical trial.
Our body and blood will still be needed for more clinical trials to broaden the indications and explore appropriate combinations.
I have posted on my speculations on what that might mean on my blog: bkoffman.blogspot.com